Sinovac Biotech
SVASinovac Biotech Ltd. (NASDAQ: SVA) is a China-based biopharmaceutical company. Its primary business is the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company operates its own proprietary manufacturing and research facilities. A key therapeutic area for Sinovac is viral vaccines. The company has developed and commercialized vaccines for several diseases, including hepatitis A and B, seasonal influenza, and the H5N1 avian influenza. Sinovac is also known for its COVID-19 vaccine, CoronaVac, an inactivated virus vaccine that has been authorized for use in numerous countries worldwide. The company's product portfolio additionally includes vaccines for mumps and enterovirus 71 (EV71), which causes hand, foot, and mouth disease. As a publicly traded entity, Sinovac Biotech's strategic focus remains on its core competency in vaccine technology platforms, particularly inactivated vaccines. The company's activities encompass the full vaccine lifecycle, from preclinical research to large-scale production and global distribution partnerships.
SVA · Stock Price
Historical price data
About
Sinovac Biotech Ltd. (NASDAQ: SVA) is a China-based biopharmaceutical company. Its primary business is the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company operates its own proprietary manufacturing and research facilities. A key therapeutic area for Sinovac is viral vaccines. The company has developed and commercialized vaccines for several diseases, including hepatitis A and B, seasonal influenza, and the H5N1 avian influenza. Sinovac is also known for its COVID-19 vaccine, CoronaVac, an inactivated virus vaccine that has been authorized for use in numerous countries worldwide. The company's product portfolio additionally includes vaccines for mumps and enterovirus 71 (EV71), which causes hand, foot, and mouth disease. As a publicly traded entity, Sinovac Biotech's strategic focus remains on its core competency in vaccine technology platforms, particularly inactivated vaccines. The company's activities encompass the full vaccine lifecycle, from preclinical research to large-scale production and global distribution partnerships.